drugset / Trial / NCT00449397

Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis

NCT00449397

Phase 3 Completed 150 enrolled AstraZeneca
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is determine the minimal effective dose and the impact on: 1. treatment outcomes at 4, 12 and/or 48 weeks the treatment has required to treat patients experiencing the first psychotic episode 2. the final maintenance doses 3. the use of other medications 4. the amount of changes to other antipsychotic medication 5. the number of hospitalization days

Timeline

Start
2003-07
Primary completion
2006-01
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 200 mg
Subject Quetiapine Small molecule 400 mg

Indications